These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 20031832

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 3. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
    Roumie CL, Choma NN, Kaltenbach L, Mitchel EF, Arbogast PG, Griffin MR.
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1053-63. PubMed ID: 19637402
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 5. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.
    Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
    [Abstract] [Full Text] [Related]

  • 6. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [Abstract] [Full Text] [Related]

  • 7. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 8. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 9. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.
    Arch Intern Med; 2005 May 09; 165(9):978-84. PubMed ID: 15883235
    [Abstract] [Full Text] [Related]

  • 10. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S.
    Pharmacoepidemiol Drug Saf; 2007 Apr 09; 16(4):366-76. PubMed ID: 16897817
    [Abstract] [Full Text] [Related]

  • 11. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.
    Arthritis Rheum; 2006 May 04; 54(5):1378-89. PubMed ID: 16645966
    [Abstract] [Full Text] [Related]

  • 13. The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
    Warner JJ, Weideman RA, Kelly KC, Brilakis ES, Banerjee S, Cunningham F, Harford WV, Kazi S, Little BB, Cryer B.
    J Cardiovasc Pharmacol Ther; 2008 Dec 04; 13(4):252-60. PubMed ID: 18787084
    [Abstract] [Full Text] [Related]

  • 14. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 04; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications.
    Velentgas P, West W, Cannuscio CC, Watson DJ, Walker AM.
    Pharmacoepidemiol Drug Saf; 2006 Sep 04; 15(9):641-52. PubMed ID: 16392153
    [Abstract] [Full Text] [Related]

  • 16. Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.
    Goldstein JL, Zhao SZ, Burke TA, Palmer R, von Allmen H, Henderson SC.
    Am J Gastroenterol; 2003 Dec 04; 98(12):2627-34. PubMed ID: 14687808
    [Abstract] [Full Text] [Related]

  • 17. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
    Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, Lüscher TF, Borer JS, Mascette AM, Husni ME, Solomon DH, Graham DY, Yeomans ND, Krum H, Ruschitzka F, Lincoff AM, Nissen SE, PRECISION Investigators.
    Am Heart J; 2009 Apr 04; 157(4):606-12. PubMed ID: 19332185
    [Abstract] [Full Text] [Related]

  • 18. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.
    J Med Assoc Thai; 2009 Dec 04; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [Abstract] [Full Text] [Related]

  • 19. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
    Hudson M, Rahme E, Richard H, Pilote L.
    Arthritis Rheum; 2007 Apr 15; 57(3):516-23. PubMed ID: 17394181
    [Abstract] [Full Text] [Related]

  • 20. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA.
    Lancet; 2007 Apr 15; 365(9458):475-81. PubMed ID: 15705456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.